Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botulinum toxin A for temporomandibular disorder-related myofascial pain
2018-001597-16Phase 4Completed
- Sponsor
- Sitnikova Victoria
- Start
- May 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, single-arm trial of botulinum toxin type A in temporomandibular disorder (TMD) and myalgia, sponsored by Sitnikova Victoria. Primary endpoints: Reduction of myofascial pain and Improvement of jaw function. Started May 2018; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
temporomandibular disorder (TMD)myalgia
Beyond the preview
Go deeper on 2018-001597-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001597-16.